The European Union Allocates Six Million Euros to Study Prevention Strategies Tumors Caused by HPV
News Nov 05, 2013
It is estimated that, in Europe , every year 30,000 women die as a result of cervical cancer, especially in the Eastern countries , where screening programs are not consolidated.
The consortium CoheaHr wants to provide scientific evidence for the clinical effectiveness and cost - effectiveness of different strategies to prevent cervical cancer throughout the European Union. To assess strategies focus on screening for HPV detection and vaccination. Specifically, the consortium conducted four clinical trials:
• Compare the results of sampling for HPV testing when performed by the patient herself and when you get a health care professional, and their possible implementation as a method to increase screening coverage.
• To determine the subsequent most appropriate time intervals and the use of HPV screening test for subsequent monitoring of :
o Women in age to start screening, vaccinated during adolescence
o Young women vaccinated two years before the start of screening.
• To assess the feasibility and acceptance of the HPV vaccine by the women entering the routine screening between 25-45 years.
The results of the different components will be incorporated into transmission models, economic and impact made by the consortium to make projections of different preventive interventions.
The consortium is committed to producing systematic reviews that allow summarizing the evidence generated in the medical literature and contribute to the dissemination of research results.
CoheaHr consortium with the participation of twelve partners from eleven countries: Amsterdam, Barcelona, Tampere, London, Turin, Stockholm, Brussels, Ljubljana, Lyon, Copenhagen, Reims and Wolfsburg. The Research Program in Cancer Epidemiology ICO lead two areas of work, the study of acceptance of the vaccine in women aged 25-45 years and scientific dissemination activities.